Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition.

Schroeder HA, Nunn KL, Schaefer A, Henry CE, Lam F, Pauly MH, Whaley KJ, Zeitlin L, Humphrys MS, Ravel J, Lai SK.

Mucosal Immunol. 2018 Jul 9. doi: 10.1038/s41385-018-0054-z. [Epub ahead of print]

PMID:
29988116
2.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy295. [Epub ahead of print]

PMID:
29982718
3.

ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.

Yang B, Schaefer A, Wang YY, McCallen J, Lee P, Newby JM, Arora H, Kumar PA, Zeitlin L, Whaley KJ, McKinley SA, Fischer WA 2nd, Harit D, Lai SK.

J Infect Dis. 2018 Aug 14;218(6):901-910. doi: 10.1093/infdis/jiy230.

PMID:
29688496
4.

Acceptability of multipurpose human papillomavirus vaccines among providers and mothers of adolescent girls: A mixed-methods study in five countries.

Vielot NA, Goldberg SK, Zimet G, Smith SB, Anne McDonald M, Ramos S, Morgan K, Joo Kim C, Richter KL, Peris M, Whaley KJ, Smith JS.

Papillomavirus Res. 2017 Jun;3:126-133. doi: 10.1016/j.pvr.2017.04.001. Epub 2017 Apr 6.

5.

Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.

Anderson DJ, Politch JA, Zeitlin L, Hiatt A, Kadasia K, Mayer KH, Ruprecht RM, Villinger F, Whaley KJ.

AIDS. 2017 Jul 17;31(11):1505-1517. doi: 10.1097/QAD.0000000000001521. Review.

6.

Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, Anderson DJ, Moss JA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02465-16. doi: 10.1128/AAC.02465-16. Print 2017 Jul.

7.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

8.

Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge.

Van Slyke G, Sully EK, Bohorova N, Bohorov O, Kim D, Pauly MH, Whaley KJ, Zeitlin L, Mantis NJ.

Clin Vaccine Immunol. 2016 Sep 6;23(9):795-9. doi: 10.1128/CVI.00088-16. Print 2016 Sep.

9.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

10.

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.

Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA.

Virology. 2016 Mar;490:49-58. doi: 10.1016/j.virol.2016.01.004. Epub 2016 Jan 30.

11.

Antibody therapeutics for Ebola virus disease.

Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP.

Curr Opin Virol. 2016 Apr;17:45-49. doi: 10.1016/j.coviro.2016.01.006. Epub 2016 Jan 27. Review.

12.

CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.

Pettit DK, Rogers RS, Arthur K, Brodsky Y, Clark RH, Crowell C, Ennis J, Gillespie A, Gillespie R, Livingston B, Nalbandian E, Pace D, Smidt P, Pauly M, Timmons K, Trentalange M, Whaley KJ, Zeitlin L, Thomas JN.

MAbs. 2016;8(2):347-57. doi: 10.1080/19420862.2015.1127492.

13.

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Oct 9;11(10):e1005212. doi: 10.1371/journal.ppat.1005212. eCollection 2015 Oct. No abstract available.

14.

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Jun 26;11(6):e1005016. doi: 10.1371/journal.ppat.1005016. eCollection 2015 Jun. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005212. Berry, Jody [corrected to Berry, Jody D].

15.

Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.

Levinson KJ, Giffen SR, Pauly MH, Kim DH, Bohorov O, Bohorova N, Whaley KJ, Zeitlin L, Mantis NJ.

J Immunol Methods. 2015 Jul;422:111-7. doi: 10.1016/j.jim.2015.04.001. Epub 2015 Apr 9.

16.

Strategies for preventing mucosal cell-associated HIV transmission.

Whaley KJ, Mayer KH.

J Infect Dis. 2014 Dec 15;210 Suppl 3:S674-80. doi: 10.1093/infdis/jiu398. Review.

17.

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.

18.

Chimeric plantibody passively protects mice against aerosolized ricin challenge.

Sully EK, Whaley KJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Pauly MH, Velasco J, Hiatt E, Morton J, Swope K, Roy CJ, Zeitlin L, Mantis NJ.

Clin Vaccine Immunol. 2014 May;21(5):777-82. doi: 10.1128/CVI.00003-14. Epub 2014 Feb 26.

19.

Plant-Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease.

Hiatt A, Whaley KJ, Zeitlin L.

Microbiol Spectr. 2014 Feb;2(1):AID-0004-2012. doi: 10.1128/microbiolspec.AID-0004-2012. Review.

PMID:
26082108
20.

Antibody-based concepts for multipurpose prevention technologies.

Whaley KJ, Zeitlin L.

Antiviral Res. 2013 Dec;100 Suppl:S48-53. doi: 10.1016/j.antiviral.2013.09.027. Epub 2013 Nov 1. Review.

21.

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG.

Sci Transl Med. 2013 Aug 21;5(199):199ra113. doi: 10.1126/scitranslmed.3006608.

22.

Multiantibody strategies for HIV.

Hiatt A, Zeitlin L, Whaley KJ.

Clin Dev Immunol. 2013;2013:632893. doi: 10.1155/2013/632893. Epub 2013 Jun 6. Review.

23.

Developing multipurpose reproductive health technologies: an integrated strategy.

Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B.

AIDS Res Treat. 2013;2013:790154. doi: 10.1155/2013/790154. Epub 2013 Feb 28.

24.

Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.

Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE Jr, Piedra PA, Gilbert BE.

MAbs. 2013 Mar-Apr;5(2):263-9. doi: 10.4161/mabs.23281. Epub 2013 Feb 8.

25.

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109. Epub 2012 Oct 15.

26.

Emerging antibody-based products.

Whaley KJ, Morton J, Hume S, Hiatt E, Bratcher B, Klimyuk V, Hiatt A, Pauly M, Zeitlin L.

Curr Top Microbiol Immunol. 2014;375:107-26. doi: 10.1007/82_2012_240. Review.

PMID:
22772797
27.

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, Olinger GG.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20690-4. doi: 10.1073/pnas.1108360108. Epub 2011 Dec 5.

28.

Emerging antibody products and Nicotiana manufacturing.

Whaley KJ, Hiatt A, Zeitlin L.

Hum Vaccin. 2011 Mar;7(3):349-56. Epub 2011 Mar 1. Review.

29.

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.

Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR.

Antiviral Res. 2010 Dec;88 Suppl 1:S55-66. doi: 10.1016/j.antiviral.2010.09.006.

PMID:
21109069
30.

High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system.

Huang Z, Phoolcharoen W, Lai H, Piensook K, Cardineau G, Zeitlin L, Whaley KJ, Arntzen CJ, Mason HS, Chen Q.

Biotechnol Bioeng. 2010 May 1;106(1):9-17. doi: 10.1002/bit.22652.

31.

Second-generation HIV microbicides: continued development of griffithsin.

Zeitlin L, Pauly M, Whaley KJ.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6029-30. doi: 10.1073/pnas.0902239106. Epub 2009 Apr 8. No abstract available.

32.

Microbicide preference among young women in California.

Holt BY, Morwitz VG, Ngo L, Harrison PF, Whaley KJ, Pettifor A, Nguyen AH.

J Womens Health (Larchmt). 2006 Apr;15(3):281-94.

PMID:
16620187
33.

Preventing transmission: plant-derived microbicides and mucosal vaccines for reproductive health.

Whaley KJ, Zeitlin L.

Vaccine. 2005 Mar 7;23(15):1819-22. Review.

PMID:
15734048
34.

Preventing sexual transmission of HSV and HIV: the challenge for active and passive immunization of mucosal surfaces.

Zeitlin L, Palmer C, Whaley KJ.

Biotechnol Genet Eng Rev. 2002;19:121-38. Review. No abstract available.

PMID:
12520875
35.

Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis.

Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA.

Sex Transm Dis. 2002 Nov;29(11):655-64.

PMID:
12438901
36.

Human monoclonal antibody stability and activity at vaginal pH.

Castle PE, Karp DA, Zeitlin L, García-Moreno E B, Moench TR, Whaley KJ, Cone RA.

J Reprod Immunol. 2002 Jul-Aug;56(1-2):61-76.

PMID:
12106884
37.

Microbicides for preventing transmission of genital herpes.

Zeitlin L, Whaley KJ.

Herpes. 2002 Apr;9(1):4-9. Review.

PMID:
11916493
38.

Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent.

Khanna KV, Whaley KJ, Zeitlin L, Moench TR, Mehrazar K, Cone RA, Liao Z, Hildreth JE, Hoen TE, Shultz L, Markham RB.

J Clin Invest. 2002 Jan;109(2):205-11.

39.

Diffusion of macromolecules and virus-like particles in human cervical mucus.

Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA.

Biophys J. 2001 Oct;81(4):1930-7.

40.

Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source.

Boskey ER, Cone RA, Whaley KJ, Moench TR.

Hum Reprod. 2001 Sep;16(9):1809-13.

PMID:
11527880
41.

Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models.

Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR.

Sex Transm Dis. 2001 Jul;28(7):417-23.

PMID:
11460027
42.

Transgenic commensals as mucosal protectants.

Whaley KJ, Zeitlin L.

Nat Biotechnol. 2000 Oct;18(10):1038-9. No abstract available.

PMID:
11017036
43.

Preventing infectious disease with passive immunization.

Zeitlin L, Cone RA, Moench TR, Whaley KJ.

Microbes Infect. 2000 May;2(6):701-8. Review.

PMID:
10884621
44.

Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens.

Talwar GP, Raghuvanshi P, Mishra R, Banerjee U, Rattan A, Whaley KJ, Zeitlin L, Achilles SL, Barré-Sinoussi F, David A, Doncel GF.

Am J Reprod Immunol. 2000 Mar;43(3):144-51.

PMID:
10735590
45.

Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.

Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA.

Infect Immun. 1999 Oct;67(10):5170-5.

46.

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Zeitlin L, Cone RA, Whaley KJ.

Emerg Infect Dis. 1999 Jan-Feb;5(1):54-64. Review.

47.

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina.

Zeitlin L, Castle PE, Whaley KJ, Moench TR, Cone RA.

J Reprod Immunol. 1998 Oct;40(1):93-101.

PMID:
9862259
48.

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes.

Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM, Russell DR, Queen C, Cone RA, Whaley KJ.

Nat Biotechnol. 1998 Dec;16(13):1361-4.

PMID:
9853620
49.

Contraceptive testing of vaginal agents in rabbits.

Castle PE, Hoen TE, Whaley KJ, Cone RA.

Contraception. 1998 Jul;58(1):51-60. Review.

PMID:
9743897
50.

Antigen-releasing polymer rings and microspheres stimulate mucosal immunity in the vagina.

Wyatt TL, Whaley KJ, Cone RA, Saltzman WM.

J Control Release. 1998 Jan 2;50(1-3):93-102.

PMID:
9685876

Supplemental Content

Loading ...
Support Center